Focused On-demand Library for NACHT, LRR and PYD domains-containing protein 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86W26

UPID:

NAL10_HUMAN

Alternative names:

Nucleotide-binding oligomerization domain protein 8

Alternative UPACC:

Q86W26; Q2M3C4; Q6JGT0

Background:

NACHT, LRR, and PYD domains-containing protein 10, also known as Nucleotide-binding oligomerization domain protein 8, plays a pivotal role in the immune response. It inhibits CASP1 autoprocessing, IL1B secretion, and PYCARD-mediated apoptosis, showcasing anti-inflammatory activity. This protein is crucial for immunity against C.albicans and bacterial infections, contributing to pro-inflammatory cytokine release. It also aids in T-cell-mediated inflammatory responses and protects against periodontitis by inducing IL1A in oral epithelial cells. Additionally, it possesses ATPase and GTPase activities.

Therapeutic significance:

Understanding the role of NACHT, LRR, and PYD domains-containing protein 10 could open doors to potential therapeutic strategies.